Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current ...

Intranasal epinephrine was administered within 1 minute of identifying the reaction or when the patient returned to the ...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth ...

The oncology adjuvants market is expanding due to rising cancer rates, personalized medicine demand, and advances in ...

Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth ...

Even the best vaccine can fail if mismanaged. Dr. Jon Townsend outlines good handling practices to protect your investment ...

Q3 2025 Earnings Call Transcript November 6, 2025 Invivyd, Inc. misses on earnings expectations. Reported EPS is $-0.06153 ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. Route 66 Warranty has three extended auto warranty plans, also called vehicle service ...

In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...